5-Amino-1MQ vs Semaglutide

5-Amino-1MQ

An orally bioavailable small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase). Plenty of compelling rodent data, almost no human data, and a forum community that has gotten ahead of the science.

Best for

Best only if you specifically want an oral, needle-free experiment and understand the evidence is preclinical and anecdotal.

Semaglutide

The GLP-1 receptor agonist that turned obesity pharmacology into a mainstream conversation. Once-weekly injection, ~7-day half-life, and the largest randomised dataset of anything in this catalogue.

Best for

Best for anyone who wants fat loss that actually shows up in trials.

5-Amino-1MQ

The mechanistic case rests on a series of papers from Pissios, Kraus, and collaborators showing NNMT inhibition produces favourable metabolic phenotypes in diet-induced obese mice. There are no completed human RCTs of 5-Amino-1MQ in the public literature as of this writing. What circulates is forum reports, practitioner anecdotes, and one or two small case series. Treat the mouse data as a strong reason the molecule is worth studying in humans, not as a substitute for the trials that have not been done.

Semaglutide

Approved by the FDA and EMA for type 2 diabetes (Ozempic, Rybelsus oral) and chronic weight management (Wegovy). The STEP 1–8 obesity trials and the SUSTAIN diabetes programme together represent tens of thousands of randomised patient-years. SELECT (2023) added cardiovascular outcomes — a 20% reduction in MACE in patients with obesity and established CVD. This is the most thoroughly characterised peptide on this site by an order of magnitude.